A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single center, non-randomized, phase Ⅱ trial to evaluate safety and
efficacy of using the combination treatment of Camrelizumab with anti-angiogenic drugs and
Chemotherapy of metastatic colorectal mucinous adenocarcinoma(MAC).